Tim Walbert

Former Chairman, President and CEO
Horizon Therapeutics

Tim Walbert served as chairman, president and Chief Executive Officer of Horizon Therapeutics from 2008 to its $28 billion sale to Amgen in October 2023. Before joining Horizon, he was president, chief executive officer and director of IDM Pharma Inc., a public biotechnology company, which was acquired by Takeda in 2009. Before IDM, Mr. Walbert served as executive vice president, commercial operations at NeoPharm Inc., a public biotechnology company. From 2001 to 2005, he was divisional vice president and general manager, immunology, at Abbott, now AbbVie, leading the global development and launch of HUMIRA and served as divisional vice president, global cardiovascular strategy. From 1991 to 2001, he also held sales and marketing roles with increasing responsibility at Searle, Merck and Wyeth.

He serves on the boards of Mirum Pharmaceuticals and Century Therapeutics. He is also a member of the National Organization for Rare Disorders (NORD) Advisory Board, the Wall Street Journal CEO Council, the cNBC CEO Council and serves on the Board of Trustees of Muhlenberg College. He is a member of Economic Club of Chicago, the Commercial Club of Chicago and the Civic Committee of the Commercial Club of Chicago. Mr. Walbert received a Bachelor of Arts in business from Muhlenberg College in Allentown, PA.